173 related articles for article (PubMed ID: 20858024)
21. Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis.
Jazirehi AR; Huerta-Yepez S; Cheng G; Bonavida B
Cancer Res; 2005 Jan; 65(1):264-76. PubMed ID: 15665303
[TBL] [Abstract][Full Text] [Related]
22. Blockage of interleukin-6 signaling with 6-amino-4-quinazoline synergistically induces the inhibitory effect of bortezomib in human U266 cells.
Park J; Ahn KS; Bae EK; Kim BS; Kim BK; Lee YY; Yoon SS
Anticancer Drugs; 2008 Sep; 19(8):777-82. PubMed ID: 18690088
[TBL] [Abstract][Full Text] [Related]
23. Targeting the NF-κB pathway in cancer therapy.
Erstad DJ; Cusack JC
Surg Oncol Clin N Am; 2013 Oct; 22(4):705-46. PubMed ID: 24012396
[TBL] [Abstract][Full Text] [Related]
24. NF-κB Signaling Pathway Inhibitors as Anticancer Drug Candidates.
de Castro Barbosa ML; da Conceicao RA; Fraga AGM; Camarinha BD; de Carvalho Silva GC; Lima AGF; Cardoso EA; de Oliveira Freitas Lione V
Anticancer Agents Med Chem; 2017; 17(4):483-490. PubMed ID: 27481554
[TBL] [Abstract][Full Text] [Related]
25. The ubiquitin proteasome system and efficacy of proteasome inhibitors in diseases.
Chitra S; Nalini G; Rajasekhar G
Int J Rheum Dis; 2012 Jun; 15(3):249-60. PubMed ID: 22709487
[TBL] [Abstract][Full Text] [Related]
26. Using NF-κB as a molecular target for theranostics in radiation oncology research.
Liu YC; Chiang IT; Hsu FT; Hwang JJ
Expert Rev Mol Diagn; 2012 Mar; 12(2):139-46. PubMed ID: 22369374
[TBL] [Abstract][Full Text] [Related]
27. Targeting NF-kappaB for colorectal cancer.
Sakamoto K; Maeda S
Expert Opin Ther Targets; 2010 Jun; 14(6):593-601. PubMed ID: 20367537
[TBL] [Abstract][Full Text] [Related]
28. Recent insights into NF-κB signalling pathways and the link between inflammation and prostate cancer.
Nguyen DP; Li J; Yadav SS; Tewari AK
BJU Int; 2014 Aug; 114(2):168-76. PubMed ID: 24215139
[TBL] [Abstract][Full Text] [Related]
29. Phase I trial of sodium salicylate in patients with myelodysplastic syndromes and acute myelogenous leukemia.
Klimek VM; Dolezal EK; Smith L; Soff G; Nimer SD
Leuk Res; 2012 May; 36(5):570-4. PubMed ID: 22154022
[TBL] [Abstract][Full Text] [Related]
30. Nuclear factor-kappaB signaling: a contributor in leukemogenesis and a target for pharmacological intervention in human acute myelogenous leukemia.
Reikvam H; Olsnes AM; Gjertsen BT; Ersvar E; Bruserud Ø
Crit Rev Oncog; 2009; 15(1-2):1-41. PubMed ID: 20136626
[TBL] [Abstract][Full Text] [Related]
31. Molecularly-targeted Strategy and NF-κB in lymphoid malignancies.
Horie R
J Clin Exp Hematop; 2013; 53(3):185-95. PubMed ID: 24369220
[TBL] [Abstract][Full Text] [Related]
32. Constitutive NF-κB activation in AML: Causes and treatment strategies.
Bosman MC; Schuringa JJ; Vellenga E
Crit Rev Oncol Hematol; 2016 Feb; 98():35-44. PubMed ID: 26490297
[TBL] [Abstract][Full Text] [Related]
33. IKK/NF-kappaB signaling: balancing life and death--a new approach to cancer therapy.
Luo JL; Kamata H; Karin M
J Clin Invest; 2005 Oct; 115(10):2625-32. PubMed ID: 16200195
[TBL] [Abstract][Full Text] [Related]
34. Nuclear factor kB as a target for new drug development in myeloid malignancies.
Cilloni D; Martinelli G; Messa F; Baccarani M; Saglio G
Haematologica; 2007 Sep; 92(9):1224-9. PubMed ID: 17666366
[TBL] [Abstract][Full Text] [Related]
35. NF-κB in cancer therapy.
Li F; Zhang J; Arfuso F; Chinnathambi A; Zayed ME; Alharbi SA; Kumar AP; Ahn KS; Sethi G
Arch Toxicol; 2015 May; 89(5):711-31. PubMed ID: 25690730
[TBL] [Abstract][Full Text] [Related]
36. NF-kappaB as a therapeutic target in cancer.
Orlowski RZ; Baldwin AS
Trends Mol Med; 2002 Aug; 8(8):385-9. PubMed ID: 12127724
[TBL] [Abstract][Full Text] [Related]
37. Inflammation and cancer: when NF-kappaB amalgamates the perilous partnership.
Dobrovolskaia MA; Kozlov SV
Curr Cancer Drug Targets; 2005 Aug; 5(5):325-44. PubMed ID: 16101381
[TBL] [Abstract][Full Text] [Related]
38. Aberrant nuclear factor-kappa B activity in acute myeloid leukemia: from molecular pathogenesis to therapeutic target.
Zhou J; Ching YQ; Chng WJ
Oncotarget; 2015 Mar; 6(8):5490-500. PubMed ID: 25823927
[TBL] [Abstract][Full Text] [Related]
39. Modulation of NF-κB Signaling as a Therapeutic Target in Autoimmunity.
Herrington FD; Carmody RJ; Goodyear CS
J Biomol Screen; 2016 Mar; 21(3):223-42. PubMed ID: 26597958
[TBL] [Abstract][Full Text] [Related]
40. [NF-kappaB inhibitor].
Nakashima J; Horiguchi Y; Ohno Y; Gondo T; Takeuchi H; Tachibana M
Nihon Rinsho; 2011 Jun; 69 Suppl 5():160-4. PubMed ID: 22207963
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
